Abstract:Background: Tinea pedis is a dermatophytosis of the feet usually occurs between the toes with the webspace between the fourth and fifth digits but, in many cases, may appear as an extensive pattern on the bottom and sides of the feet. Terbinafine and itraconazole were evaluated with the efficacy/effectiveness and toxicity in the systemic treatment of Tinea pedis and compared with each other. Objective: To compare the efficacy and safety of terbinafine vs. itraconazole in treating tinea pedis. Materials and Methods: A total of 50 patients were selected, and they were divided into groups (group-A and group B), each of which included 25 patients. Group A was given oral Terbinafine 250 mg daily for two weeks. Group B was given oral Itraconazole 200mg daily for the same duration. Patients were observed for the efficacy and side effects of the trial medicines. A baseline complete blood picture, liver and renal function test, and urine analysis were done and repeated frequently during therapy. Results: Most patients were in the fourth decade in both groups, and the male-to-female ratio was almost 4:1. Two groups of people were studied: group-A with terbinafine 250 mg daily and group B with itraconazole 200 mg daily for 14 days. Evaluated weekly during treatment and 02 weeks after cessation of therapy, and finally on 08th week to see the clinical improvement and adverse effects. The clinical response was found in chronic hyperkeratotic type: 08/08, 08/08; chronic interdigital type: 07/07, 07/06; vesico-bullous type: 06/05, 06/05; Mixed type: 04/03, 03/02 in group-A and group-B respectively. On average, 92% clinical improvement was found in group-A and 84% in group B. Most patients had nausea (20.0%) followed by 08% diarrhea in group A. On the other hand, in group B, most patients had nausea (28.0%), followed by 4.0% fatigue and 4.0% diarrhea, and only 01 patient found elevated liver enzyme but did not exceed the upper limit. 80% of patients in the terbinafine group had transient, mild to moderate nausea. Conclusion: No significant differences in efficacy and toxicity were found between terbinafine and itraconazole groups. Terbinafine may represent a good alternative for treating Tinea Pedis in patients who cannot take itraconazole or other available drugs due to contraindications. TAJ 2022; 36: No-1: 75-82

The Safety and Efficacy of Terbinafine in the Treatment of Elderly Patients with Onychomycosis: a Multicenter Trial

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Efficacy and influence on the blood glucose when treated with terbinafine for onychomycosis in patients with diabetes mellitus

Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium

Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study

Meta-analysis on Efficacy and Safety of Terbinafine and Itraconazole in Treatment of Onychomycosis

Combination Treatment of Oral Terbinafine with Topical Terbinafine and 10% Urea Ointment in Hyperkeratotic Type Tinea Pedis.

A Long-Term Clinical Study on Oral Terbinafine Combined with Topical Bifonazole Cream for Tinea Pedis Treatment

The Clinical Effect of XTR Combined with Terbinafine in 46 Patients with Toenail Onychomycosis

Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis

Short-term Oral Terbinafine Combined with Topical Bifonazole Cream Treating Moderate and Severe Tinea Pedis

Study on Efficacy and Safety of Terbinafine Vs. Itraconazole in the Treatment of Tinea Pedis

Self-control study of Ultra-pulse carbon dioxide laser combined with butenafine ointment in the treat-ment of onychomycosis

Long‐term follow‐up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patients

Extended Use of Topical Efinaconazole Remains Safe and Can Provide Continuing Benefits for Dermatophyte Toenail Onychomycosis

Observition of Therapeutic Effect of Terbinafine and Pevisone Cream in the Treatment of Candidal Balanoposthitis

Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis

Evaluation of efficacy and safety of 1% luliconazole cream in the treatment of tinea pedis

Terbinafine: An update

A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin